TWP 201
Alternative Names: TWP-201Latest Information Update: 28 Jun 2024
At a glance
- Originator Shandong TheraWisdom Biopharm
- Class Follicle stimulating hormones; Immunoglobulin Fc fragments; Infertility therapies; Recombinant fusion proteins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Female infertility
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Female-infertility(In volunteers) in China (SC, Injection)
- 17 May 2021 Phase-I clinical trials in Female infertility (In volunteers) in China (SC) (NCT04878705)
- 07 May 2021 Shandong TheraWisdom Biopharma plans a phase I trial in Female infertility (In volunteers) in China in May 2021 (SC, Injection) (NCT04878705)